ViewRay
MR-guided radiotherapy pioneer. Founded in 2004 by James Dempsey (physicist) at the University of Florida. Developed the first commercial MR-IGRT system (originally with cobalt-60 sources, later with a conventional linac), establishing the MR-linac as a clinical category before competitor Elekta shipped Unity. As of 2023, the company entered Chapter 11 bankruptcy with restructuring and asset transition since.
Company history
- 2004 — founded; concept of integrated MR + radiotherapy with real-time cine imaging during delivery.
- 2012 — first MRIdian Cobalt-60 MR-IGRT system ships (0.35T MRI + 3 cobalt-60 sources). First commercial MR-guided RT platform.
- 2017 — MRIdian Linac replaces the cobalt configuration (0.35T MRI + 6 MV linac). Existing cobalt installs offered an upgrade path.
- 2018 onward — competes head-on with Elekta Unity (1.5T MR-Linac) in a narrow but high-visibility segment.
- 2023 — Chapter 11 bankruptcy filing; asset transactions and restructuring follow. Installed base continues to operate; future product trajectory under restructured ownership.
Product line
- MRIdian — 0.35T MR-Linac with 6 MV photon delivery, real-time cine MRI during delivery, adaptive RT workflow.
- MRIdian Linac (current configuration) — post-cobalt upgrade path on existing installs.
- Treatment planning + adaptive workflow software — MRIdian-specific contouring and re-planning tools tightly coupled to the platform.
Distinctive technology vs. Unity
- 0.35T MRI (vs Unity's 1.5T) — lower field simplifies beam–magnet physics interaction at the cost of weaker soft-tissue contrast on the imaging side. The clinical trade-off is at the heart of the platform's competitive position.
- Real-time cine MRI during delivery with low latency — beam-on visualization of moving targets, with gating against tumor displacement (rather than predicted-motion management).
- Adaptive RT workflow — daily online adaptation against the MR-of-the-day, scaled to high-fraction-volume sites.
Clinical niche
Strongest advocacy and outcomes literature in pancreatic SBRT, adrenal SBRT, and oligometastatic ablative RT where real-time tumor visualization at delivery is the load-bearing differentiator. MR-guided dose escalation in pancreas adenocarcinoma is the most-cited clinical narrative for the platform.
Market position
Very small unit volume — dozens of installs globally as of mid-2020s, concentrated at major academic and tertiary cancer centers. Competes directly with Elekta Unity in the narrow MR-Linac segment. Post-bankruptcy product roadmap and parts-and-service continuity are program-level decisions for current operators; installed base continues to treat patients.
Refurb posture
- No meaningful refurb market at current installed-base size — capital and operational complexity preclude secondary-market activity at this stage.
- Service continuity under restructured ownership is the primary lifecycle risk; programs evaluate that explicitly.
- Cobalt-to-linac upgrades on legacy 2012-era installs were vendor-led; not a refurb pathway.